How Bon Secours Mercy runs its own PBM

Advertisement

Bon Secours Mercy Health uses its pharmacy benefit manager only for claims processing and network access. Everything else it runs itself, including its formulary, network design and claims audits.

The Cincinnati-based system manages pharmacy benefits for about 100,000 covered lives, including its own associates and several business clients. It runs those benefits through its own pharmacy enterprise, Harness Health, which includes retail, home delivery, specialty and home infusion pharmacies.

Habib Abraham, director of pharmacy benefits at Bon Secours Mercy Health, discussed the model during a fireside chat at Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit in Chicago. He said the system logged more than $36 million in savings through its pharmacy benefit programs, not counting rebates.

Editor’s note: Responses have been lightly edited for length and clarity.

Question: How is your model different from a traditional PBM arrangement?

Habib Abraham: Historically, the system had a traditional PBM model with one of the big three PBMs, restricted to their networks and their rates. A few years before I joined, we moved to a different PBM and took over our pharmacy benefit management internally. We’re a custom client with a custom formulary. We use our PBM more as a pharmacy benefit administrator. They do the back-end adjudication of claims, and we leverage their network and relationships when it aligns with our incentives. But at the end of the day, we have the say in what our network looks like, what our formulary looks like and what drugs we do or don’t cover.

We also have a maintenance fill model. Patients can fill a new maintenance medication once at a network retail pharmacy. After that, we require them to use our in-house home delivery or retail pharmacies.

Q: Where does the $36 million in savings come from?

HA: It’s not rebates. Rebates are completely separate, and that number is actually higher. The savings come from being a custom client with a closed formulary and from bringing a lot of prescriptions in-house. Since biosimilars came out, we’ve highly favored them as appropriate, as long as they’re not on shortage and there’s enough financial incentive. We also focus on moving prescriptions to 90-day supplies and on removing drugs from our formulary that may be wasteful spend.

Q: Who checks the math?

HA: Because we’re our own health plan and our own PBM, we audit our plan ourselves. We work off a cost-plus model, so we know exactly how much a drug should cost. I can log into our wholesaler and see that drug X costs Y. I know what the markup and dispensing fee are supposed to be, so we can audit claims and confirm the drug was charged appropriately. We can also see whether patients are stockpiling medications and why. We meet with our broker at least once a week, and they help us manage and audit our PBM relationship.

Q: What breaks when you switch models?

HA: The biggest issues usually aren’t with the pharmacy benefit itself. A lot of times it’s eligibility: whether members came over correctly or are showing up twice or not at all. Then there’s continuity of care, making sure everyone who had a prior authorization or step therapy in place still has it. You try to dot every I and cross every T, but you know there’s going to be some disruption. Because we work directly with our pharmacies, they have a direct line to our team. If it’s a prior authorization issue and we can confirm they had it in place before, we can jump in and adjust it so patients get their medications.

Q: “Transparent” has become a buzzword. What does it mean to you?

HA: It means knowing exactly how much we’re paying for our drugs. We can go into our wholesaler websites, see the price per unit, look at a claim and know what that prescription should cost. That’s what we pay, because we’re also a pay-as-billed model. It helps that we’re a health system that buys its own drugs.

Q: How many associates use the system’s pharmacies?

HA: Probably 85% to 90% of our associates come through our pharmacy in one fashion or another. That’s largely by plan design, because the maintenance fill rule funnels those prescriptions in-house. Our home delivery pharmacy is licensed in about 46 states, and we should have all 50 by the start of next year.

Members also get faster service. Anyone can call their PBM for a vacation override, but who knows how long you’ll be on the line. A quick note to us, and we can handle it in less than a minute.

Q: Does recent PBM legislation change your leverage?

HA: Absolutely. The Consolidated Appropriations Act built on a lot of the work employer-based plans have been doing for years. It spells out that rebates, payments, remuneration and financial incentives of any kind from pharma to the PBM must be passed through to the plan. That’s one less thing to fight for in contract negotiations, but it should be your baseline, not the finish line.

The CAA provisions don’t take effect until Aug. 3, 2028, at the earliest, and Jan. 1, 2029, for all plans. There’s work you can do between now and then to strengthen your contract language.

Q: What contract terms should leaders insist on?

HA: Any remuneration, incentives or rebates should pass through to the plan. If you’re working off rebate guarantees, understand exactly what your PBM is guaranteeing, which drugs are excluded and why. Make sure you have audit rights to see what was excluded. Just because something is excluded from a rebate guarantee doesn’t mean you’re not entitled to those rebates. You want the ability to check dollar for dollar, claim for claim.

Q: Have the big three PBMs been willing to work with your model?

HA: We’ve gone to the big three several times and shown them our model. They said, “No, thanks. You customize too much, and it’s not worth our effort.” Which is fine. They’re just not a fit for us. We work with a midsize PBM that doesn’t have its own specialty or home delivery pharmacies, so it lets us customize and use our own.

For systems without these capabilities, I’d say partner with other health systems if you can. Maybe they have capabilities you’re still working to build.

Q: Does this only work for large systems?

HA: You don’t have to be a multistate, multihospital health system to move away from a traditional PBM model. Maybe it’s just unbundling your rebates and working with a rebate aggregator, or using your PBM only for claims processing. Take it piece by piece. Price out each part, look at other vendors and decide whether it makes sense to stay or carve it out.

Q: How do you convince HR and finance leaders who worry about losing rebate revenue?

HA: The challenge is shifting mindsets from chasing rebates to lowest net cost. You can get a lot of rebates if you’re spending a lot of money. Ask whether your PBM can tell you exactly how much money is leaving your account, net-net. If they can’t, that’s a problem. You wouldn’t do this anywhere else. Someone asks you for money, you give it to them and they say, “We’ll give you a rebate.” How much? “We’ll find out.” It doesn’t work anywhere else, so why have we been doing it this way for so long?

Q: Who owns the PBM relationship at Bon Secours Mercy?

HA: HR’s signature is on the contract, but our pharmacy team is heavily involved in the day-to-day. We meet with our PBM multiple times a week and with HR and our broker at least weekly. HR looks to our team for guidance, so we sit between the PBM and HR.

Advertisement

Next Up in Pharmacy

Advertisement